TABLE 5.

Isa pharmacokinetic parameters

Mean ± SD (Geometric mean) [CV%]	Cohort A1: cHL (anti‐PD‐1/PD‐L1 naïve) (n = 17)	Cohort A2: cHL (anti‐PD‐1/PD‐L1 progressors) (n = 12)	Cohort B: DLBCL (n = 14)	Cohort C: PTCL (n = 7)	All (N = 50)
C max	226 ± 48.1	265 ± 38.8	253 ± 29.1	181 ± 35.7	237 ± 47.1
(μg/ml)	(221) [21]	(262) [15]	(251) [12]	(178) [20]	(232) [20]
t max‎ a	5.95	5.23	5.26	4.57	5.17
(h) b	(2.00–8.92)	(3.00–8.83)	(2.60–10.5)	(2.33–7.45)	(2.00–10.5)
AUC1 week	22,500 ± 5770	26,600 ± 4030	23,700 ± 4960	15,000 ± 4680	22,700 ± 6030
(μg•h/mL)	(21,800) [26]	(26,300) [15] c	(23,200) [21]	(14,300) [31]	(21,800) [27] d

^a Median.

^b Min–max.

^c n = 11.

^d n = 49.

Abbreviations: AUC, area under curve; cHL, classic Hodgkin's lymphoma; C _max, maximum concentration; CV, coefficient of variation; DLBCL, diffuse large B‐cell lymphoma; Isa, isatuximab; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PTCL, peripheral T‐cell lymphoma; SD, standard deviation; t _max, time to reach C _max.